Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Jesús S. Mora,Angela Genge,Adriano Chiò,Conrado J. Estol,Delia Chaverri,Maria Hernández,SaÚl MarÍn,Javier Mascias,Gabriel E. Rodríguez,Mónica Povedano,Andres Paipa,Raúl Domínguez,Josep Gamez,Maria Salvado,Christian Lunetta,Carlos Ballario,Nilo Riva,Jessica Mandrioli,Alain Moussy,Jean-Pierre Kinet,Christian Auclair,Patrice Dubreuil,Vincent Arnold,Colin Mansfield,Olivier Hermine

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

2019

AbstractObjective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or masitinib at 4.5 ...

Keywords:

Placebo
Clinical trial
Cohort
Physical therapy
Medicine
Clinical endpoint
Masitinib
Riluzole
Internal medicine
Population
Randomized controlled trial
Amyotrophic lateral sclerosis
in patient
Oncology
Tyrosine-kinase inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations